TY - JOUR
T1 - Perspectives on the production, and use, of rapid evidence in decision making during the COVID-19 pandemic
T2 - A qualitative study
AU - Clyne, Barbara
AU - Hynes, Lisa
AU - Kirwan, Colette
AU - McGeehan, Máire
AU - Byrne, Paula
AU - Killilea, Martha
AU - Smith, Susan M.
AU - Ryan, Máirín
AU - Collins, Claire
AU - O'Neill, Michelle
AU - Wallace, Emma
AU - Murphy, Andrew W.
AU - Kelly, Maureen E.
N1 - Publisher Copyright:
© 2022 Authors. All rights reserved.
PY - 2022/6/30
Y1 - 2022/6/30
N2 - Objectives To describe perceptions of providing, and using rapid evidence, to support decision making by two national bodies (one public health policy and one front-line clinical practice) during the COVID-19 pandemic. Design Descriptive qualitative study (March-August 2020): 25 semistructured interviews were conducted, transcribed verbatim and thematically analysed. Setting Data were obtained as part of an evaluation of two Irish national projects; the Irish COVID-19 Evidence for General Practitioners project (General Practice (GP) project) which provided relevant evidence to address clinical questions posed by GPs; and the COVID-19 Evidence Synthesis Team (Health Policy project) which produced rapid evidence products at the request of the National Public Health Emergency Team. Participants Purposive sample of 14 evidence providers (EPs: generated and disseminated rapid evidence) and 11 service ssers (SUs: GPs and policy-makers, who used the evidence). Main outcome measures Participant perceptions. Results The Policy Project comprised 27 EPs, producing 30 reports across 1432 person-work-days. The GP project comprised 10 members from 3 organisations, meeting 49 times and posting evidence-based answers to 126 questions. Four unique themes were generated. € The Work' highlighted that a structured but flexible organisational approach to producing evidence was essential. Ensuring quality of evidence products was challenging, particularly in the context of absent or poor-quality evidence. € The Use' highlighted that rapid evidence products were considered invaluable to decision making. Trust and credibility of EPs were key, however, communication difficulties were highlighted by SUs (eg, website functionality). € The Team' emphasised that a highly skilled team, working collaboratively, is essential to meeting the substantial workload demands and tight turnaround time. € The Future' highlighted that investing in resources, planning and embedding evidence synthesis support, is crucial to national emergency preparedness. Conclusions Rapid evidence products were considered invaluable to decision making. The credibility of EPs, a close relationship with SUs and having a highly skilled and adaptable team to meet the workload demands were identified as key strengths that optimised the utilisation of rapid evidence. Ethics approval Ethical approval was obtained from the National Research Ethics Committee for COVID-19-related Research, Ireland.
AB - Objectives To describe perceptions of providing, and using rapid evidence, to support decision making by two national bodies (one public health policy and one front-line clinical practice) during the COVID-19 pandemic. Design Descriptive qualitative study (March-August 2020): 25 semistructured interviews were conducted, transcribed verbatim and thematically analysed. Setting Data were obtained as part of an evaluation of two Irish national projects; the Irish COVID-19 Evidence for General Practitioners project (General Practice (GP) project) which provided relevant evidence to address clinical questions posed by GPs; and the COVID-19 Evidence Synthesis Team (Health Policy project) which produced rapid evidence products at the request of the National Public Health Emergency Team. Participants Purposive sample of 14 evidence providers (EPs: generated and disseminated rapid evidence) and 11 service ssers (SUs: GPs and policy-makers, who used the evidence). Main outcome measures Participant perceptions. Results The Policy Project comprised 27 EPs, producing 30 reports across 1432 person-work-days. The GP project comprised 10 members from 3 organisations, meeting 49 times and posting evidence-based answers to 126 questions. Four unique themes were generated. € The Work' highlighted that a structured but flexible organisational approach to producing evidence was essential. Ensuring quality of evidence products was challenging, particularly in the context of absent or poor-quality evidence. € The Use' highlighted that rapid evidence products were considered invaluable to decision making. Trust and credibility of EPs were key, however, communication difficulties were highlighted by SUs (eg, website functionality). € The Team' emphasised that a highly skilled team, working collaboratively, is essential to meeting the substantial workload demands and tight turnaround time. € The Future' highlighted that investing in resources, planning and embedding evidence synthesis support, is crucial to national emergency preparedness. Conclusions Rapid evidence products were considered invaluable to decision making. The credibility of EPs, a close relationship with SUs and having a highly skilled and adaptable team to meet the workload demands were identified as key strengths that optimised the utilisation of rapid evidence. Ethics approval Ethical approval was obtained from the National Research Ethics Committee for COVID-19-related Research, Ireland.
KW - COVID-19
KW - Evidence-Based Practice
KW - PRIMARY CARE
KW - Public health
KW - QUALITATIVE RESEARCH
UR - http://www.scopus.com/inward/record.url?scp=85134845754&partnerID=8YFLogxK
U2 - 10.1136/bmjebm-2021-111905
DO - 10.1136/bmjebm-2021-111905
M3 - Article
C2 - 35772940
AN - SCOPUS:85134845754
SN - 2515-446X
VL - 28
SP - 48
EP - 57
JO - BMJ Evidence-Based Medicine
JF - BMJ Evidence-Based Medicine
IS - 1
ER -